skip to main content

The Potential Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in Elderly People and Clinical Risk Groups in the UK: A Lifetime Multi-Cohort Model.(Research Article)

Van Bellinghen, Laure - Anne ; Meier, Genevieve ; Van Vlaenderen, Ilse

PLoS ONE, June 6, 2014, Vol.9(6) [Peer Reviewed Journal]

Full text available

View all versions
Citations Cited by
  • Title:
    The Potential Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in Elderly People and Clinical Risk Groups in the UK: A Lifetime Multi-Cohort Model.(Research Article)
  • Author: Van Bellinghen, Laure - Anne ; Meier, Genevieve ; Van Vlaenderen, Ilse
  • Subjects: Influenza Vaccines -- Economic Aspects ; Influenza Vaccines -- Models ; Database Industry -- Economic Aspects ; Database Industry -- Models ; Medical Economics -- Economic Aspects ; Medical Economics -- Models ; Markov Processes -- Economic Aspects ; Markov Processes -- Models ; Influenza -- Economic Aspects ; Influenza -- Models
  • Is Part Of: PLoS ONE, June 6, 2014, Vol.9(6)
  • Description: Objective To estimate the potential cost-effectiveness of quadrivalent influenza vaccine compared with trivalent influenza vaccine in the UK. Methods A lifetime, multi-cohort, static Markov model was constructed, with nine age groups each divided into healthy and at-risk categories. Influenza A and B were accounted for separately. The model was run in one-year cycles for a lifetime (maximum age: 100 years). The analysis was from the perspective of the UK National Health Service. Costs and benefits were discounted at 3.5%. 2010 UK vaccination policy (vaccination of people at risk and those aged [greater than or equal to]65 years) was applied. Herd effect was not included. Inputs were derived from national databases and published sources where possible. The quadrivalent influenza vaccine price was not available when the study was conducted. It was estimated at #194;#163;6.72,15% above the trivalent vaccine price of #194;#163;5.85. Sensitivity analyses used an incremental price of up to 50%. Results Compared with trivalent influenza vaccine, the quadrivalent influenza vaccine would be expected to reduce the numbers of influenza cases by 1,393,720, medical visits by 439,852 complications by 167,357, hospitalisations for complications by 26,424 and influenza deaths by 16,471. The estimated base case incremental cost-effectiveness ratio (ICER) was #194;#163;5,299/quality-adjusted life-year (QALY). Sensitivity analyses indicated that the ICER was sensitive to changes in circulation of influenza virus subtypes and vaccine mismatch; all other parameters had little effect. In 96% of simulations the ICER was #194;#163;20,000/QALY. Since this analysis was completed, quadrivalent influenza vaccine has become available in the UK at a list price of #194;#163;9.94. Using this price in the model, the estimated ICER for quadrivalent compared with trivalent vaccination was #194;#163;27,378/QALY, still within the NICE cost-effectiveness threshold (#194;#163;20,000-#194;#163;30,000). Conclusions Quadrivalent influenza vaccine could reduce influenza disease burden and would be cost-effective compared with trivalent influenza vaccine in elderly people and clinical risk groups in the UK.
  • Language: English
  • Identifier: ISSN: 1932-6203

Searching Remote Databases, Please Wait